Monash Ivf Group Ltd · ASX:MVF
Monash Ivf — Shareholder Meeting (November 2017)
23 slides from Monash Ivf's shareholder meeting presentation, Nov 24, 2017
Slide 1: Annual General Meeting
Annual General Meeting 24 November 2017
Slide 2: Disclaimer
Disclaimer The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) (“MVF”) (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF’s activities as at the date of this presentation. The information does not purpo
Slide 3: Chairman's address
Chairman’s address Richard Davis 3 Monash IVF Group | Annual General Meeting 2017
Slide 4: Key Achievements
Key Achievements Focus on developing industry leading science & technology Strategic positioning as the leading premium service provider Earnings increase despite decline in Patient Treatments KL Fertility in Malaysia continues growth trajectory – Investment to support Market share only de
Slide 5: FY2018 Trading Update and H1FY2018 Outlook
FY2018 Trading Update • Australian stimulated cycles market increased by 4.3% in the first quarter predominately from low-cost IVF sector that we strategically don’t participate in • Our Australian stimulated cycles market share declined by 2.5% in the first quarter representing a 6.6% decline in ou
Slide 6: Thank you / Welcome
Thank you • Senior Management Team • Our passionate doctors, nurses, scientists and support staff providing superior patient care • Shareholders for continued support Welcome • David Morris – Commenced 13/11/17 • Experience in healthcare, international business development and strategy setting & exe
Slide 7: CEO Introduction
CEO Introduction David Morris 7 Monash IVF Group | Annual General Meeting 2017
Slide 8: Introduction
Introduction • Honoured and excited to join such an innovative company that is at the forefront of fertility treatment. • Passionate about Life Sciences and Healthcare. • Energised when I am working for a cause; especially one that changes people’s lives. • Build on our success based on good science
Slide 9: CFO Presentation
CFO Presentation Michael Knaap 9 Monash IVF Group | Annual General Meeting 2017
Slide 10: Overview of Monash IVF Group
Overview of Monash IVF Group Core Assisted Diagnostic and Ancillary Ultrasound Reproductive Services Services 22 clinics 2 specialised 17 clinics laboratories in Victoria 5 service centres and South Australia 17 Sonologists 89 Fertility Specialists 3 Australian states 3 day hospitals
Slide 11: Track record of strong financial performance
Track record of strong financial performance Number of Patient Treatments¹ Revenue ($m) 156.6 155.2 17901 17410 15861 125.0 14287 114.0 12582 96.3 FY13 FY14 FY15 FY16 FY17 FY13 FY14 FY15 FY16 FY17 4 Year CAGR3 of 8.5% 4 Year CAGR3 of 12.7% EBITDA5 ($m) NPAT ($m) 49.6 49.0 28.8 29.6 39.7 38.8 22.6 21
Slide 12: Financial and Operational Highlights
Financial and Operational Highlights 12 Monash IVF Group | Annual General Meeting 2017
Slide 13: FY17 Financial Highlights
FY17 Financial Highlights Revenue EBITDA1 Total FY17 Dividend $155.2m $49.0m 8.8c FY16 $156.6m FY16 $49.6m FY16 8.5 cents Down 0.9% on pcp Down 1.2% on pcp Up 3.5% on pcp NPAT Cash Conversion2 Basic EPS $29.6m 93.9% 12.6c FY16 $28.8m FY16 $99.1% FY16 12.2 cents Up 2.9% on pcp Down 5.2% on pcp Up 3.3
Slide 14: FY2017 Operational Highlights
FY2017 Operational Highlights Monash IVF’s Australian IVF market share only declined marginally in FY17, demonstrating the strength and resilience of its premium offering Monash IVF’s ultrasound scan volumes declined in FY17 Strong cost control and efficient work practices limited EBITDA margi
Slide 15: Australian IVF market movement
Australian IVF market movement Stimulated Cycle Growth Rates in Key Markets1 15.0% The Australian IVF Market softened in FY17 against 12.3% very strong comparative volumes in the pcp 9.3% 10.0% 7.5% 7.4% Total Key Markets1 Stimulated Cycles increased by 0.2% in FY17 vs pcp (compared to FY16 grow
Slide 16: Australian market share – IVF
Australian market share – IVF Stimulated Cycle3 Market Share Australia Key Markets2 22.4% 25.2% Stimulated Cycle3 market share in Australia decreased by 0.5% to 22.4% vs pcp; Stimulated Cycle market share in Key Markets2 decreased by 0.9% to 25.2% vs pcp; 77.6% 74.8% Monash IVF Other Patient Treat
Slide 17: Expanding domestic & brand consolidation
Expanding domestic & brand consolidation Acquisitions, New New Monash Ultrasound for Women clinic opened in Berwick, Melbourne in August 2016 Locations & Medical New women’s ultrasound services commenced in Adelaide, South Australia from November 2016 and Gold Coast from July 2017 Specialists
Slide 18: International FY17 overview
International FY17 overview • KL Fertility Continued strong growth in volumes achieved as new fertility specialists continue to gain traction – Patient Treatments up 10.1% Relocated to state of art new IVF facility in May 2017 – signs are very positive, reflected through patient feedback and str
Slide 19: Our Brands and Marketing
Our Brands and Marketing 19 Monash IVF Group | Annual General Meeting 2017
Slide 20: FY18 - Trading Update
FY18 - Trading Update 20 Monash IVF Group | Annual General Meeting 2017
Slide 21: FY2018 Trading Update
FY2018 Trading Update Stimulated Cycle Growth Rates in Key Markets1 Australian Stimulated Cycle market grows above long-term growth rate in Q1FY18, driven by low cost 15.0% 12.3% IVF sector Total Key Market1 Stimulated Cycles increased by 4.6% in Q1FY18 10.0% vs pcp (decline of 2.9% in Q1FY17 vs p
Slide 22: FY18 Trading Update - Continued
FY18 Trading Update - Continued KL Fertility in Malaysia is settled in the new, state of the art facility which is flowing through to strong demand growth in Q1FY18 Complementing MVF’s women’s imaging services, our investment to in- house Non Invasive Prenatal Testing (NIPT) is delivering to pla
Slide 23: Annual General Meeting
Annual General Meeting 24 November 2017 Monash IVF Group | Annual General 23 Meeting 2017
Monash IVF Group — Shareholder Meeting (November 2017) on 6ix